General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Teva Naloxone Nasal Spray (naloxone hydrochloride)
Status:
Concluded with an LOI
Manufacturer:
Teva Canada Ltd.
Indication:
Opioid overdose, known or suspected, for emergency use
Last updated October 8, 2024
Status:
Concluded without agreement
Manufacturer:
Paladin Labs Inc.
Indication:
Epilepsy, partial-onset seizures
Last updated October 4, 2024
Status:
Negotiations were not pursued
Manufacturer:
Sobi Canada Inc.
Indication:
Chronic Immune Thrombocytopenia
Last updated October 3, 2024
Status:
Negotiations were not pursued (No supply available in Canada)
Manufacturer:
Novo Nordisk Canada Inc.
Indication:
Growth hormone deficiency
Last updated September 26, 2024
Status:
Concluded with an LOI
Manufacturer:
AbbVie Corporation
Indication:
Migraine, prevention
Last updated September 25, 2024
Status:
Concluded with an LOI
Manufacturer:
BioCryst Pharmaceuticals Inc.
Indication:
Hereditary Angioedema
Last updated September 12, 2024
Status:
Concluded with an LOI
Manufacturer:
Duchesnay Inc.
Indication:
Contraceptive, oral
Last updated September 11, 2024
Yescarta (axicabtagene ciloleucel)
Status:
Concluded with an LOI
Manufacturer:
Gilead Sciences Canada Inc.
Indication:
Follicular lymphoma (FL), Relapsed or refractory, grade 1, 2 or 3a, in adult patients after two or more lines of systemic therapy
Last updated September 6, 2024
Yescarta (axicabtagene ciloleucel)
Status:
Concluded with an LOI
Manufacturer:
Gilead Sciences Canada Inc.
Indication:
Diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL), in adult patients, that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy
Last updated September 6, 2024
Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
Von Hippel-Lindau (VHL) disease in adult patients who require therapy for associated non-metastatic renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or non-metastatic pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.
Last updated August 30, 2024